Rising like the phoenix?
Rising like the phoenix?
复制标题
像凤凰一样崛起？
DOI：
10.1161/atvbaha.114.304486
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Das,Mitali
中科院分区：
文献类型：
--
作者：
Plow,EdwardF;Das,Mitali
这是将RUC-4或其衍生物开发为治疗药物的漫长道路上的第一步。即使在临床前水平，仍需证明该药物不会引起临床显著出血或不会导致血栓形成发作，因为药物会消散或具有其他不良反应。此外，适当的临床试验的设计和这种试验的成本代表了心血管竞技场中药物开发的主要障碍。然而，重要的一步已经实现-新的αIIbβ3拮抗剂的可能性已经上升。
the initial step in a long road to the development of RUC-4 or its derivatives as a therapeutic drug. Even at the preclinical level, it remains to be shown that the drug does not cause clinically significant bleeds or does not lead to thrombotic episodes because the drug dissipates or has other adverse effects. Moreover, the design of appropriate clinical trials and the cost of such trials represent major hurdles to the drug development in the cardiovascular arena. Nevertheless, an important step has been come to realization—the possibility of a new αIIbβ3 antagonist may have risen.